Abstract
Background: Ustekinumab is a fully human monoclonal antibody which binds Interleukin (IL)-12/23. It is indicated for the treatment of moderate-severe psoriasis and active psoriatic arthritis. Few data are available about the possibility of an interaction between ustekinumab and the liver.
Case Description: We reported a case of a 61-year old woman admitted to our Unit for severe transaminase elevation (aspartate transaminase 756 IU/l, alanine transaminase 1212 IU/l) occurred after a single Ustekinumab infusion for psoriasis. All other possible causes of liver damage, including drugs, hepatitis viruses, auto-antibodies and metabolic disorders were excluded. Liver biopsy showed lymphocytic infiltration, biliary duct damage and piecemeal necrosis. On the bases of the nonspecific histological picture and Rucam score, we accomplished the diagnosis of “liver injury of iatrogenic origin”. After drug withdrawal, a spontaneous normalization of liver enzymes occurred within six months.
Keywords: Ustekinumab, drug-induced liver injury, transaminase elevation, liver, adverse events, HBV, HCV.
Current Drug Safety
Title:A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal
Volume: 13 Issue: 3
Author(s): Rosa Lovero, Giuseppe Losurdo, Marcella Mastromauro, Nicola Maurizio Castellaneta, Antonio Mongelli, Antonietta Gentile, Alfredo Di Leo and Mariabeatrice Principi*
Affiliation:
- Section of Gastroenterology, Department of Emergency and Organ Transplantation, AOU Policlinico, University of Bari, Bari,Italy
Keywords: Ustekinumab, drug-induced liver injury, transaminase elevation, liver, adverse events, HBV, HCV.
Abstract: Background: Ustekinumab is a fully human monoclonal antibody which binds Interleukin (IL)-12/23. It is indicated for the treatment of moderate-severe psoriasis and active psoriatic arthritis. Few data are available about the possibility of an interaction between ustekinumab and the liver.
Case Description: We reported a case of a 61-year old woman admitted to our Unit for severe transaminase elevation (aspartate transaminase 756 IU/l, alanine transaminase 1212 IU/l) occurred after a single Ustekinumab infusion for psoriasis. All other possible causes of liver damage, including drugs, hepatitis viruses, auto-antibodies and metabolic disorders were excluded. Liver biopsy showed lymphocytic infiltration, biliary duct damage and piecemeal necrosis. On the bases of the nonspecific histological picture and Rucam score, we accomplished the diagnosis of “liver injury of iatrogenic origin”. After drug withdrawal, a spontaneous normalization of liver enzymes occurred within six months.
Export Options
About this article
Cite this article as:
Lovero Rosa , Losurdo Giuseppe , Mastromauro Marcella , Castellaneta Maurizio Nicola , Mongelli Antonio , Gentile Antonietta , Di Leo Alfredo and Principi Mariabeatrice *, A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal, Current Drug Safety 2018; 13 (3) . https://dx.doi.org/10.2174/1574886313666180719165212
DOI https://dx.doi.org/10.2174/1574886313666180719165212 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Herpes Labialis: An Update
Recent Patents on Inflammation & Allergy Drug Discovery Validation of a Phage Display Method for Protease Inhibitor Selection Using SFTI and HiTI Synthetic Hybrid Peptides
Combinatorial Chemistry & High Throughput Screening Protective Immunity in Humans: A Glimpse Provided by the Analysis of Herpesvirus-Specific T Cells in Health and Disease
Current Immunology Reviews (Discontinued) A Case of Multiple Sclerosis with Protracted Course of COVID-19
Infectious Disorders - Drug Targets Fatty Acid-Binding Proteins at a Glance
Protein & Peptide Letters Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry From Raynaud’s Phenomenon to Very Early Diagnosis of Systemic Sclerosis- The VEDOSS approach
Current Rheumatology Reviews Therapeutic Potential of Antileukotriene Drug-<i>Camellia sinensis</i> Extract Co-Formulation on Histamine Induced Asthma in Guinea Pigs
Current Drug Research Reviews SIGIRR / TIR8: A Negative Regulator of Toll-IL-1R Signaling
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Meet Our Associate Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Perspectives in Therapeutic Innovation in Ocular Surface Disorders and Dry Eye Syndrome
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Vitamin D status in coronary artery disease: association with IL-35 and TGF-β1 and disease severity
Endocrine, Metabolic & Immune Disorders - Drug Targets Interaction of Mesalasine (5-ASA) with Translational Initiation Factors eIF4 Partially Explains 5-ASA Anti-Inflammatory and Anti-Neoplastic Activities
Medicinal Chemistry Non Pharmacological Strategies to Promote Spinal Cord Regeneration: A View on Some Individual or Combined Approaches
Current Pharmaceutical Design Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design Targeting Nitrosative Stress for Neurovascular Protection: New Implications in Brain Diseases
Current Drug Targets Studies on Anticancer Activities of Lactoferrin and Lactoferricin
Current Protein & Peptide Science Establishment of Novel Cells Stably Secreting Various Human IL-18 Recombinant Proteins
Current Pharmaceutical Biotechnology Biophysical and Structural Characterization of the Recombinant Human eIF3L
Protein & Peptide Letters Combination Therapy for the Treatment of Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry